BofA lowered the firm’s price target on RxSight (RXST) to $36 from $60 and keeps a Buy rating on the shares. Shares are down 61% since hitting all-time highs in June 2024 as the stock re-rated after inline Q3/Q4 results and a generally tougher macro environment for high growth, not yet profitable medtech companies, the analyst tells investors in a research note. The firm thinks the stock could be rangebound near-term with only an inline Q1.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Path to Profitability: A Buy Rating Amid Revenue Growth and Operational Leverage
- RxSight price target lowered to $28 from $33 at Stifel
- Promising Growth and Competitive Edge: A Buy Rating for RxSight
- RxSight, Inc. Reports Strong Revenue Growth Amid Challenges
- RxSight price target lowered to $44 from $58 at BTIG
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue